Tag: Tirzepatide
Eli Lilly says tirzepatide reduces OSA severity
June 24, 2024HME News Staff
INDIANAPOLIS – Eli Lilly’s tirzepatide demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo, according to the company’s SURMOUNT-OSA phase 3 clinical trials evaluating the drug for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, with and without CPAP therapy.
In a key secondary endpoint, the company...
New weight loss drug reduces AHI in certain patients
April 17, 2024HME News Staff
INDIANAPOLIS – Eli Lilly and Company’s tirzepatide injection diabetes and weight loss drug may help reduce AHI in patients with sleep apnea, according to the results of the company’s phase 3 clinical trials. The Surmount-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were not on PAP therapy for 52 weeks. Tirzepatide led to a mean AHI reduction from baseline of 27.4 events per hour compared to a mean AHI reduction from baseline of 4.8 events...